Pathogenesis and Molecular Therapy of Brain Tumor
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 15 December 2025 | Viewed by 811
Special Issue Editor
Interests: glioma; glioblastoma; DNA-methylation; epigenetics; computational pathology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Brain tumors show unique and special molecular features. Glioblastoma is the most frequent primary brain tumor of adults. It shows an aggressive behavior and a poor prognosis. Despite intensive research on targeted therapy, there is still no curative therapy. In the current 2021 WHO Classification of CNS tumors, novel genetic and epigenetic aspects contributing to glioblastoma initiation and progression are highlighted. The most common genetic alterations in brain tumors are IDH1/2 mutations, TERT mutations, and CDKN2A/B deletions. Furthermore, brain tumors show aberrant DNA-methylation landscapes altering numerous biological pathways. This leads to an intimate relationship of tumor initiation and progression with the tumor microenvironment. Therefore, it is necessary to understand genetic and epigenetic mechanisms occurring in glioblastomas in order develop advanced therapy strategies.
In this Special Issue, we shall discuss advances in understanding the pathogenesis of brain tumors and reveal novel molecular therapy approaches. We invite basic and translational as well as clinical researchers to contribute to this Special Issue. We look forward to receiving your contributions.
Dr. Theo Kraus
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- brain tumor
- glioma
- glioblastoma
- astrocytoma
- oligodendroglioma
- epigenetics
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
